LEXINGTON, Mass. & SYDNEY–(BUSINESS WIRE)–GI Dynamics, Inc. (ASX: GID), a medical device company providing innovative treatments for type 2 diabetes and obesity, today announced data showing improvement in glucose metabolism following treatment with EndoBarrier® Therapy (duodenal-jejunal bypass liner or DJBL) that comes significantly close to improvement achieved with gastric bypass surgery (RYGB) in obese patients with type 2 diabetes. In a poster titled, ‘Improvement in Glucose Metabolism after Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Duodenojejunal Bypass,’ Dr. Jürgen Stein, Department of Gastroenterology and Clinical Nutrition, Hospital Sachsenhausen, Frankfurt, Germany, presented these findings at the American Gastroenterological Association’s annual Digestive Disease Week (DDW) meeting in Washington, D.C.

This is the first study comparing the improvement in glucose metabolism following gastric bypass surgery, considered the ‘gold standard’ of metabolic surgery, to the less invasive endoscopic placement of the EndoBarrier device. Preliminary data demonstrate that both procedures have a similar impact on diabetes remission and significant impact on body weight: RYGB (Δ HbA1c, -1.1%, Δ bw – 28.2 kg; Δ BMI – 10.4 kg/m2 ), DJBL (Δ HbA1c, -1.4%, Δ bw – 22.9 kg; Δ BMI – 8.8 kg/m2 ).

“It is interesting to observe how EndoBarrier treatment compares to bariatric surgery when administered at the same clinical center in the hands of independent researchers,” said David Maggs, M.D., chief medical officer of GI Dynamics. “This is another important milestone that manifests the potential for device intervention while avoiding the alteration of anatomy by surgery.”

These data show that EndoBarrier, specifically designed to mimic the duodenal-jejunal exclusion created by gastric bypass surgery, has a significant impact on glucose homeostasis at one, three and nine months of therapy, which can reduce the reliance patients may have on diabetes medications.